MBD4缺陷可预测转移性葡萄膜黑色素瘤患者对免疫检查点抑制剂的应答
该回顾性队列纳入300例接受免疫检查点抑制剂(ICI)治疗的转移性葡萄膜黑色素瘤(mUM)患者,其中131例肿瘤行MBD4测序,5例(3.8%)存在MBD4突变。MBD4突变与更好的客观缓解率、无进展生存期和总生存期相关,作者认为MBD4突变对ICI应答、PFS和OS获益有高度预测作用。
要点
- 300例mUM患者中客观缓解率为3.3%,临床获益率为10%。
- 131例测序肿瘤中5例(3.8%)存在MBD4突变。
- MBD4突变患者中3/5应答,而MBD4野生型患者应答率为4%(p < 0.001)。
核心结论
- 在mUM患者中,MBD4突变对ICI的应答、PFS和总生存期获益有高度预测作用。
- 作者认为MBD4可能是一种组织不可知生物标志物,并建议在mUM及其他已报道MBD4突变的肿瘤类型中进行测序。
研究设计与样本
- 回顾性队列研究,纳入接受ICI治疗的mUM患者300例。
- 对其中一部分患者进行了MBD4测序,共131例肿瘤完成测序。
- 中位随访时间为17.3个月。
主要发现
- 300例mUM患者中观察到10例客观缓解和20例稳定疾病超过12个月,对应客观缓解率3.3%、临床获益率10%。
- 131例测序肿瘤中5例(3.8%)存在MBD4突变。
- MBD4突变与更好的客观缓解率相关:MBD4突变患者5例中3例应答,而MBD4野生型患者应答率为4%(p < 0.001)。
- 这5例应答者中,3例分别在2.8、13.9和22.3个月时出现疾病进展。
- MBD4野生型患者中位PFS为4.0个月,MBD4突变患者为22.3个月(HR = 0.22;p = 0.01)。
临床怎么用
- 作者建议在mUM以及其他已报道MBD4突变的肿瘤类型中进行MBD4测序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant to immune checkpoint inhibitors (ICI), the first reported MBD4-mutated (MBD4m) patient responded to ICI, suggesting that MBD4 mutation may predict response to ICI. METHODS: Retrospective cohort of mUM patients treated with ICI. MBD4 was sequenced in a subset of these patients. RESULTS: Three hundred mUM patients were included. Median follow-up was 17.3 months. Ten patients with an objective response and 20 cases with stable disease for >12 months were observed, corresponding to an objective response rate of 3.3% and a clinical benefit (i.e., responder patients and stable disease) rate of 10%. Of the 131 tumors sequenced for MBD4, five (3.8%) were mutated. MBD4 mutation was associated with a better objective response rate as three out of five MBD4m versus 4% of MBD4 wild-type patients responded (p < 0.001). Of these five responders, three presented progressive disease at 2.8, 13.9, and 22.3 months. Median PFS was 4.0 months in MBD4 wild-type and 22.3 months in MBD4m patients (HR = 0.22; p = 0.01). Median OS in MBD4def patients was unreached as compared to 16.6 months in MBD4pro (HR = 0.11; 95% CI: 0.02-0.86; log-rank p-test = 0.04; Fig. 2e). CONCLUSIONS: In mUM patients, MBD4 mutation is highly predictive for the response, PFS, and overall survival benefit to ICI. MBD4 could be a tissue-agnostic biomarker and should be sequenced in mUM, and other tumor types where MBD4 mutations are reported.
引用
- Saint-Ghislain M, Derrien AC, Geoffrois L, et al. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022. PMID: 35863105. doi:10.1016/j.ejca.2022.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。